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The objective of the current study was to formulate mucoadhesive controlled release matrix tablets of 
flurbiprofen and to optimize its drug release profile and bioadhesion using response surface methodology. 
Tablets were prepared via a direct compression technique and evaluated for in vitro dissolution parameters 
and bioadhesive strength. A central composite design for two factors at five levels each was employed 
for the study. Carbopol 934 and sodium carboxymethylcellulose were taken as independent variables. 
Fourier transform infrared (FTIR) spectroscopy studies were performed to observe the stability of the 
drug during direct compression and to check for a drug–polymer interaction. Various kinetic models 
were applied to evaluate drug release from the polymers. Contour and response surface plots were 
also drawn to portray the relationship between the independent and response variables. Mucoadhesive 
tablets of flurbiprofen exhibited non-Fickian drug release kinetics extending towards zero-order, with 
some formulations (F3, F8, and F9) reaching super case II transport, as the value of the release rate 
exponent (n) varied between 0.584 and 1.104. Polynomial mathematical models, generated for various 
response variables, were found to be statistically significant (P<0.05). The study also helped to find the 
drug’s optimum formulation with excellent bioadhesive strength. Suitable combinations of two polymers 
provided adequate release profile, while carbopol 934 produced more bioadhesion.
Uniterms: Flurbifrofen/mucoadhesive controlled release tablets/formulation. Flurbifrofen/mucoadhesive 
controlled release tablets/in vitro evaluation. Drugs/release profile. Drugs/bioadhesion. Tablets/direct 
compression.
O objetivo do presente estudo foi formular comprimidos mucoadesivos de flurbiprofeno, de liberação 
controlada, e otimizar o perfil da liberação do fármaco e a bioadesão, utilizando a metodologia de superfície 
de resposta. Prepararam-se os comprimidos via técnica de compressão direta, que foram avaliados in vitro 
quanto aos parâmetros de dissolução e da força bioadesiva. Planejamento com componente central para 
dois fatores em cinco níveis cada foi empregado para esse estudo. Carbopol 934 e carboximetilcelulose 
sódica foram tomados como variáveis independentes. Efetuaram-se estudos de espectroscopia por 
transformada de Fourier (FTIR) para observar a estabilidade do fármaco durante a compressão direta e 
para avaliar a interação a fármaco-polímero. Aplicaram-se vários métodos cinéticos para avaliar a liberação 
do fármaco dos polímeros. Gráficos de superfície de contorno e de resposta foram efetuados para retratar 
a relação entre as variáveis dependentes e a resposta. Os comprimidos mucoadesivos de flurbiprofeno 
apresentaram cinética de liberação não-fickiana, estendendo para ordem zero, para algumas formulações 
(F3, F8 e F9), alcançando transporte super caso II, à medida que o valor do expoente (n) de taxa de 
liberação variou entre 0,584 e 1,104. Modelos matemáticos polinomiais, gerados por diversas variáveis 
de resposta, foram estatisticamente, significativos (P<0,05). O estudo também auxiliou a encontrar a 
formulação ótima do fármaco, com excelente força de bioadesão. Combinações adequadas dos dois 
polímeros resultaram em perfis de liberação adequado, sendo que o Carbopol 934 produziu mais adesão. 
Unitermos: Flurbifrofeno/comprimidos mucoadesivos de liberação controlada/formulação. Flurbifrofeno/
comprimidos mucoadesivos de liberação controlada/avaliação in vitro. Fármacos/perfil de liberação. 
Fármacos/bioadesão. Comprimidos/compressão direta.
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INTRODUCTION
Oral controlled release systems continue to be the 
most popular of all the drug delivery systems available, 
despite the advancements made in other drug delivery 
systems (Ponchel, Irache, 1998). Conventional oral dosage 
forms often produce fluctuations in drug plasma levels 
that either exceed safe therapeutic levels or quickly fall 
below the minimum effective levels; this effect is usually 
entirely dependent upon the particular agent’s biologic 
half-life, frequency of administration, and its release rate 
(Theeuwes et al., 1983).
Mucoadhesive delivery systems offer many 
advantages over other oral controlled release systems; they 
prolong the residence time of the drug in the gastrointestinal 
tract and they target and localize the dosage form at a 
specific site (Lavelle, 2001; Hou, Cowles, Berner, 2003). 
Mucoadhesive formulations are known to provide close 
contact between the dosage form and the mucus membrane, 
resulting in high drug flux through the absorbing tissue 
(Woodley, 2001; Singh, Chakkal, Ahuja, 2006).
Inflammatory processes cause many oral cavity 
diseases, which can be treated with flurbiprofen, a potent 
anti-inflammatory, analgesic, and antipyretic agent 
belonging to the family of propionates. Its shorter half-
life (2–6 hours) limits its extensive use when compared 
to many of the newer agents, possibly because it requires 
around-the-clock administration and has harmful 
gastric side effects (Dollery, 1991). Flurbiprofen, when 
administered as conventional tablets, has been reported to 
exhibit fluctuations in plasma drug levels, which can result 
in either the manifestation of side effects or in the reduction 
of drug levels at the receptor site (Vaithiyalingam et al., 
2001). Thus, a mucoadhesive controlled release tablet 
of flurbiprofen, which maintains plasma concentrations 
effectively over a 24-hour period, and which has the ability 
to avoid gastric-related adverse effects will heighten its 
area of application.
In the development of the mucoadhesive controlled 
release dosage form, an important issue to address was 
to design an optimized formulation using a minimum 
number of experiments within a short amount of time. 
For this reason, a computer optimization technique, 
based on response surface methodology (RSM) utilizing 
a polynomial equation has been widely used. RSM is 
a collection of statistical and mathematical techniques 
that has been successfully used to determine the 
effects of several variables while optimizing processes 
(Atkinson,Donev, 1992). RSM is an extensively practiced 
approach in the development and optimization of drug 
delivery devices (Dave et al., 2004; Singh et al., 2005a; 
Singh et al., 2005b). The technique requires minimal 
experimentation and time, thus proving to be less laborious 
and time-consuming, but it is also more cost-effective than 
other approaches that are required for the optimization of 
a process. The different types of RSM designs available 
may include central composite design (CCD), three-level 
factorial design, Box–Behnken design, and D-optimal 
design (Box, Wilson, 1951). In the present study, CCD 
is employed to fit a second-order polynomial by a least 
squares technique. An equation is also used to describe 
how the test variables affect the response and determine 
the interrelationship among the variables.
The aim of this study was to develop and optimize 
an oral mucoadhesive controlled release tablet of 
flurbiprofen using RSM, as it may prove to be more 
fruitful than the conventional controlled release systems 
by virtue of prolongation of the drug residence time in the 
gastrointestinal tract. The computer-aided optimization 
technique using a CCD was employed to study the effect 
of two independent variables (factors) (i.e., the amounts 
of two mucoadhesive swellable polymers) on drug release 
profiles and bioadhesive strength.
MATERIALS AND METHODS
Materials
The materials used in the study include flurbiprofen, 
which was donated by Hamaz Pharmaceuticals (Pvt.) 
Ltd. Multan, Pakistan. High-viscosity grade carbopol 934 
(CP) and sodium carboxymethylcellulose (SCMC) were 
donated by Friends Pharmaceuticals (Pvt.) Ltd., Lahore, 
Pakistan. Gastric mucosa of rabbit was obtained from the 
rabbit at the university animal house. Analytical grade 
potassium dihydrogen phosphate, sodium hydroxide, 
magnesium stearate, lactose, and other chemicals were 
purchased from E. Merck Co, Darmstadt, Germany.
Formulation of mucoadhesive compressed matrix 
tablets
Table I shows varying amounts of polymers (i.e., 
CP and SCMC), along with the diluents (lactose) and 
calculated amount of lubricant (1% w/w magnesium 
stearate). The drug and all of the excipients, except for 
the lubricant, were homogeneously blended in a plastic 
bag for 15 minutes, followed by further blending of 5 
minutes after the addition of the lubricant. The blend was 
then directly compressed into flat-faced tablets (500 mg) 
at a constant compression load using a single-punch tablet 
machine (Emmy, Pakistan).
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Experimental design
A CCD with α = 1.414 was employed as per the 
standard protocol (Shah et al., 2009; Singh et al., 2005c). 
The amounts of CP (X1) and SCMC (X2) were selected as 
the factors, which were studied at five levels each. The 
central point (0,0) was studied in quintuplicate. All other 
formulation and processing variables were kept invariant 
throughout the study. Tables II and III summarize an 
account of the 13 experimental runs studied, their factor 
combinations, and their translation of coded levels to 
the experimental units employed during the study. The 
percent release at 4 hours (rel4h), the percent release at 12 
hours (rel12h), and bioadhesive strength f were taken as the 
response variables.
Evaluation of tablets
Physical evaluation of tablets
Tablets were evaluated for weight variation (n=20), 
hardness (n=10), thickness (n=10), and friability (n=10).
Fourier transform infrared spectroscopy
Fourier transform infrared (FTIR) spectroscopy 
using attenuated total reflectance (ATR) technology for 
active drug, tablet before, and tablet after compression 
were taken using Bruker FTIR (Tensor 27 series; Bruker 
Corporation, Billerica, USA), and OPUS data collection 
software (Bruker Corporation) was used to evaluate 
the interaction between the drug and the polymers in 
the matrix tablets before and after compression. Small 
amounts of powdered samples were directly placed onto 
the pike miracle ATR cell in such a way that the sample 
covered the ZnSe crystal surface, and the arm of the 
assembly was rotated so that a compact sample mass was 
formed onto the cell and scanned over a range of 4000 cm–1 
to 400 cm–1. Before taking the spectrum of any sample, a 
blank background scan was performed with an empty cell 
plate. The procedure described above was then repeated 
after placing the sample to be analyzed onto the pike 
miracle ATR cell.
In vitro drug release studies
Automatic USP dissolution apparatus-II (paddle 
method), attached with an auto-sampler (Watson 
Marlo, Stockholm, Sweden) was used to determine 
the drug release profile of all mucoadhesive matrix 
tablets in triplicate. Six tablets from each formulation 
were subjected to dissolution studies. Phosphate buffer 
maintained at a pH of 6.8 in a volume of 900 mL was 
selected as the dissolution medium and maintained at 
37 °C (±0.5 °C). The paddle was rotated with a rotation 
speed of 50 rpm. Then, 10 μm sintered filters (Pharma Test, 
Hainburg, Germany) were used to filter aliquots of about 
5 mL, withdrawn at 0, 0.5, 1.0, 1.5, 2.0, 4.0, 8.0, 12.0, 16.0, 
20.0, and 24.0 hours via auto-sampler. Collected samples 
were analyzed at 247 nm using a spectrophotometer, and 
drug release profiles were evaluated by drawing them 
in Microsoft Excel software (Microsoft Corporation, 
Redmond, WA, USA).
Measurement of ex vivo bioadhesive strength
Bioadhesive strength of mucoadhesive tablets, 
measured as the force of detachment against rabbit 
gastric mucosa, was determined using a modification of 
the weighing assembly. The rabbit’s mucosal membrane 
was made clear from underlying connective and adipose 
tissue and then excised and equilibrated at 37 °C±1 °C in 
phosphate buffer for 30 minutes. Mucoadhesive tablets 
from each batch, under a constant weight of 5 g, were 
then placed onto the mucosal membrane for 1 minute. The 
force required to detach the mucoadhesive tablet from the 
mucosa was regarded as the bioadhesive strength, and it 
was measured in terms of weight in grams.
Release modeling
Drug release kinetics are assumed to reflect the 
different release mechanisms of controlled release matrix 
TABLE I - Composition of different ingredients used per tablet
Ingredients Amounts (mg)
Flurbiprofen 200
Carbopol 934 34.47–140.53
Sodium carboxymethylcellulose 34.47–140.53
Magnesium stearate 5.0
Lactose (q.s) 500
TABLE II - Detail of coded levels in actual units for the selected variables at five levels
Coded level –2 –1 0 1 2
X1: carbopol 934 (mg) 34.47 50.00 87.50 125.00 140.53
X2: sodium carboxymethylcellulose (mg) 34.47 50.00 87.50 125.00 140.53
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systems. Therefore, four kinetic models were applied 
to analyze the drug release data to find the best fitting 
equation (Philip, Pathak, 2006). These models are zero-
order, first-order, Higuchi, and Korsmeyer-Peppas, as 
given in Equations 1-4:
 Qt = k0 t (1)
 logQt = log Q0 k1t (2)
 Qt = kH t1/2 (3)
 = kM
M
KP
t
∞
t
n  (4)
where: Qt is the amount of drug released at time t; Q0 is 
the initial amount of the drug in the formulation, k0, k1, kH, 
and kKP are the release rate constants for zero-order, first-
order, Higuchi model, and Korsmeyer–Peppas models, 
respectively. In Equation 4, Mt and M∞ are the amount 
of drug released at time t and ∞, while n is the diffusion 
coefficient.
Optimization of statistical data analysis
Multiple linear regression analysis (MLRA) was 
performed using Design Expert software® (Design 
Expert trial version 7.0.0; Stat-Ease, Inc., Minneapolis, 
MN, USA). A second-order polynomial model was then 
constructed using the results, including interaction and 
quadratic terms, along with linear terms. In general, the 
MLRA model can be represented as follows:
Y = β0 + β1X1 + β2X2 + β11X12 + β22X22 + β12X1X2 (5)
where: Y is the selected response; β0 is the intercept 
representing the arithmetic mean of all experimental runs 
performed; β1 and β2 are the coefficients of the linear terms; 
β11 and β22 are the coefficients of the quadratic terms; β12 is 
the coefficient of the interaction terms calculated by the 
observed experimental response values of Y, X1 and X2 are 
the coded levels of independent variables; X12 and X22 are 
the quadratic terms, and X1X2 is the interaction term.
Design expert software was also used to evaluate 
statistical validity of the constructed polynomial models by 
performing one-way analysis of variance (ANOVA). Two-
dimensional contour and three-dimensional surface plots 
were also drawn for each response variable, depending on 
the respective polynomial model. These plots served as a 
very good tool for analyzing the interaction effects of the 
studied dependent variables (Shah et al., 2009; Mandal 
et al., 2007).
RESULTS AND DISCUSSION
Physical evaluation of tablets
The results for the physical evaluation of the tablets 
showed that all batches of tablets were within the limits 
of the United States Pharmacopeia. Tablet weights varied 
between 498.52 mg and 501.79 mg (mean: 500.43 mg), 
hardness between 12.39 kg cm–2 and 19.1 kg cm−2 (mean: 
14.34 kg cm−2), thickness between 4.37 mm and 4.63 mm 
(mean: 4.56 mm), and friability ranged between 0.22% 
and 0.64% (mean: 0.46%).
Fourier transform infrared spectroscopy
FTIR spectra of pure flurbiprofen (Figure 1) and 
mucoadhesive controlled release powder mixture before 
compression (Figure 2) and after compression (Figure 3) 
did not show any change in the identified peaks. The main 
peak of the drug remained unaffected after compression, 
which indicates the stability of drug. Therefore, it was 
concluded that applied compression force has no effect on 
drug stability, and no polymer interaction and deformation 
was observed during the entire course of tablet preparation. 
FTIR spectra of flurbiprofen showed characteristic 
broad peaks of the drug in the range of 3500 cm−1 to 
2500 cm−1 because of hydrogen bonding. Conversely, 
the characteristic peaks of the drug at 1697 cm−1 and 
2935 cm−1 were indicative of carbonyl and hydroxyl 
TABLE III - Different combination of factors for the experimental 
design selected
Trial no. Trial code
Coded factor levels
X1 X2
I. F1 –2 0
II. F2 –1 –1
III. F3 –1 1
IV. F4 0 –2
V. F5 0 0
VI. F6 0 2
VII. F7 1 –1
VIII. F8 1 1
IX. F9 2 0
X. F10 0 0
XI. F11 0 0
XII. F12 0 0
XIII. F13 0 0
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FIGURE 1 - FTIR spectrum of flurbiprofen.
FIGURE 2 - FTIR spectrum of the tablet mixture (F9) containing flurbiprofen before compression.
FIGURE 3 - FTIR spectrum of tablet (F9) containing flurbiprofen after compression.
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stretching, respectively. These FTIR studies are found to 
be in line with previous studies, suggesting that there was 
drug stability during the direct compression technique 
(Shah et al., 2009).
In vitro drug release studies
Table IV lists various kinetic models computed for 
all the controlled release mucoadhesive formulations. 
Flurbiprofen release data was evaluated by zero-order, 
first-order, and Higuchi models. It is depicted in the tables 
that some formulations follow zero-order patterns for the 
release of the drug, with an observed general trend of 
more linearity in the regression line for formulations that 
have almost double the concentration of either polymer, 
such as F3, F6, F7, and F9. Most of the formulations 
follow first-order release patterns because the plots of the 
percent cumulative drug release versus the square root of 
time were found to be linear, with regression coefficient 
(R2) values ranging from 0.9289 to 0.9864 for the nine 
formulations. Hence, the mechanism of drug release from 
the matrices was found to be diffusion-controlled. The 
Higuchi model failed to explain the release mechanism 
because the dissolution of the controlled release matrix 
tablets followed the anomalous release behavior (a 
combination of diffusion and erosion). Hence, the release 
data were subjected to the Korsmeyer–Peppas equation, 
which is used to describe anomalous release behavior 
from the matrix tablets. In the present study, the values 
of n, calculated per the algorithm proposed by Peppas 
and Sahlin (1989), ranged between 0.5840 and 1.1040. 
Generally, the release pattern was found to be non-
Fickian, as it tended to approach zero-order, while some 
formulations reached super case II transport, especially 
when high levels of both polymers were combined. The 
values of the kinetic constant (kkp), which is a direct 
function of matrix solubility, were found to decline with 
increases in the amount of either polymer (Korsmeyer et 
al., 1983; Korsmeyer et al., 1983a). It should be noted that 
k1 has much lower values when compared to k0, clearly 
indicating that the release of the drug was primarily 
controlled by Fickian diffusion, along with the varying 
contribution of the polymer relaxation (case II transport) 
mechanism as well. It was observed that swelling and 
erosion (case II transport) of the tablets go on to increase 
in association with an increase in the content of any of 
the polymers.
Table V and Figure 4 show that the values of the 
drug released at 4 hours (rel4hrs) decreased noticeably from 
48.786%, which was observed at low levels of both of the 
polymers, to as low as 10.032%, which was observed at 
high levels of both of the polymers. This finding indicated 
the substantial release-retarding potential of the polymers 
for flurbiprofen. The initial burst release of the drug 
was shown by the formulations with lower amounts of 
polymers, which is due to the dissolution of the drug that 
is initially present at the surface of the matrices, and due to 
the presence of higher amounts of unreleased drug present 
in the specific dosage form (Suryakanta et al., 2011). 
Another reason for the initial burst release of the drug 
TABLE IV - Dissolution data modeling showing the release kinetics of flurbiprofen controlled release matrix tablets containing 
CP and SCMC
Formulation code
Zero order 1st order Higuchi Korsmeyer–Peppas
R2 R2 R2 N
F1 0.8391 0.9861 0.9391 0.610
F2 0.8135 0.9864 0.9457 0.584
F3 0.9732 0.9348 0.8557 0.920
F4 0.8095 0.9755 0.9205 0.601
F5 0.9678 0.9671 0.9147 0.788
F6 0.9698 0.9753 0.8926 0.830
F7 0.9733 0.9795 0.9262 0.778
F8 0.9869 0.9289 0.8193 1.104
F9 0.9890 0.9319 0.8490 0.991
F10 0.9664 0.9639 0.9146 0.786
F11 0.9683 0.9662 0.9121 0.794
F12 0.9639 0.9673 0.9193 0.774
F13 0.9704 0.9655 0.9110 0.799
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is that the dosage forms, in the early dissolution period, 
primarily exhibit first-order Fickian diffusion mechanisms. 
Higher amounts of the drug released due to Fickian 
diffusion (i.e., due to k1), as compared to that released 
due to polymer relaxation (i.e., due to k2), in the early 
time periods could also be a cause of initial burst release. 
The cumulative proportion of the drug released due to 
the case II relaxational transport constant (k2) increased 
for all of the formulations in association with increasing 
dissolution time periods, indicating that the release was 
significantly influenced by polymer relaxation in the later 
stages. However, formulations showed little burst effect at 
higher polymer levels, ratifying better sustenance of drug 
release (Singh, Chakkal, Ahuja, 2006).
Almost 88.912%-99.894% of flurbiprofen is 
released from all 13 formulations at 24-hour time intervals, 
which signifies almost complete drug release from all of 
the formulations. Hence, the overall rate of the drug release 
data (until 12 hours) was determined (as shown in Table V 
and Figure 4) via observation based on indiscriminating 
drug release for all of the formulations until a period of 24 
hours. The rate of the drug release (until 12 hours) tended 
to decrease with increase amounts of either CP or SCMC. 
According to literature findings, the slowing effect of both 
polymers is due to increases in the viscosity of the gel layer 
around the matrix tablet (Ford, Rubinstein, Hogan, 1985; 
Vazques et al., 1992). Both polymers have a tendency of 
forming gel when they come into contact with water. So, at 
high levels, hydrogel concentrations are increased around 
the tablet, and so is the viscosity of the gel layer, which 
results in decreases in the effective diffusion coefficient of 
the drug, which then consequently limits the release of the 
drug from the matrix (Skoug et al., 1993). Gel formation 
occurs due to dissociation of the carboxyl groups of CP at a 
pH above their pKa (i.e., 6.0±0.5), which causes uncoiling 
and the expansion of molecules due to the production of 
an electrostatic repulsive force between the negatively 
charged carboxyl groups. Uncoiling and expansion of the 
molecules result in polymer swelling and, consequently, 
gel is formed, which consists of closely packed swollen 
particles. With increases in the amount of polymer, this 
gelling property increases, and thicker gel restrains water 
penetration, which ultimately reduces the release of the 
drug (Singh, Chakkal, Ahuja, 2006; Suryakanta et al., 
2011). At high levels of both polymers, a considerable 
fraction of the drug (~44%) remained unreleased until 12 
TABLE V - Formulations according to the central composite design with observed responses
Trial code
Coded Factor levels Y1 (percent release 
at 4 hours)
Y2 (percent release 
at 12 hours)
Y3 (Bioadhesive 
strength in g)X1 X2
F1 –2 0 44.245 86.378 15
F2 –1 –1 48.786 87.751 12
F3 –1 1 18.796 68.004 28
F4 0 –2 48.363 91.024 14
F5 0 0 26.610 59.662 23
F6 0 2 22.914 58.184 31
F7 1 –1 25.871 58.184 33
F8 1 1 10.032 43.611 38
F9 2 0 14.044 56.705 38
F10 0 0 27.666 60.718 23
F11 0 0 26.082 59.873 21
F12 0 0 27.138 60.296 22
F13 0 0 25.871 59.556 23
FIGURE 4 - In vitro drug release profile of flurbiprofen from 
directly compressed mucoadhesive tablets containing CP and 
SCMC.
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hours, which can eventually lead to significant reductions 
in the extent of bioavailability.
Measurement of ex vivo bioadhesive strength
Bioadhesive strengths of all 13 formulations are 
presented in Figure 5, which depicts a great variation among 
the bioadhesive strengths of the formulation. A general 
trend of increasing bioadhesive strength was observed with 
increases in either of the polymer’s contents, and maximum 
strength (f) was seen with the highest levels of the two 
polymers. Formulations showed significant differences in 
bioadhesive strength and decreases in the order of F9> F8> 
F7> F6> F3> F5> F1> F4> F2 from 38 g to 12 g. This is in 
agreement with literature findings that both polymers have 
a tendency to swell immediately when they come in direct 
contact with the hydrated mucus membrane (Peppas, Sahlin, 
1996). Uncoiling of polymer chains occurs as a result of 
water sorption, which is responsible for reductions in glass 
transition temperatures below room conditions. These 
uncoiled chains eventually result in subsequent increases in 
chain mobility. The reduced glass-rubbery transition makes 
polymers plasticized, which increases the polymer surface 
area for maximum contact with the mucus membrane and 
it also increases chain flexibility for interpenetration into 
the mucus membrane (Duchen, Touchar, Peppas, 1988) 
There is no citation in the reference part! Please, white it. 
Therefore, an increase in the amount of polymer results in 
the provision of a greater surface area and more polymer 
chains for interpenetration with mucin, resulting in the 
augmentation of bioadhesive strength (Ponchel et al., 1987).
RSM optimization results
CCD, with two factors at five levels, was selected 
for the study with 13 experimental runs. Table V consists 
of responses of selected independent variables (X1 and 
X2) in terms of the percent release at 4 hours (Y1), the 
percent release at 12 hours (Y2), and force of detachment 
or bioadhesive strength (Y3) required for the detachment 
of the tablet from the mucus membrane.
Mathematical modeling
Design Expert software (version 7.0.0) was used 
to establish mathematical relationships in the form 
of polynomial equations using MLRA for the studied 
response variables, as expressed in Equations 6, 7, and 8.
Y1 = 30.54 – 6.07X1 - 6.67X2 –3.41X12 – 3.39X22 + 
1.54X1X2  (6)
Y2 = 60.02 – 11.99X1 – 10.10X2 + 3.59X12 + 5.12X22 + 
1.29X1X2  (7)
Y3 = 22.20 + 7.94X1 + 5.63X2 + 2.96X12 + 0.96X22 – 
2.75X1X2  (8)
Polynomial equations consist of coefficients for the 
intercept, first-order main effects, interaction terms, and 
higher-order effects. The relative influence of each factor 
on overall response can be signified from the sign and 
magnitude of the main effects, where a positive sign would 
be considered to have a synergistic (positive) effect, while 
a negative sign would indicate an antagonistic (negative) 
effect. Design Expert software was also used to evaluate 
the statistical validity of the constructed polynomial 
equations by performing one-way analysis of variance 
(ANOVA), as shown in Tables VI, VII, and VIII for Y1, 
Y2, and Y3, respectively. Using a 1.414% significance 
level, a model is considered significant if the P-value 
(significance probability value) is less than 0.05 (Shah et 
al., 2009; Vijayalakshmi et al., 2008). The slowing effect 
of both independent variables X1 (CP) and X2 (SCMC) is 
depicted in Equation 6, which shows that both polymers 
have a negative effect on Y1, with a slightly more negative 
effect in the case of SCMC, confirming its release rate 
slowing ability. In Table VI, the value of P is less than 
0.05 for linear contributions of X1 (CP) and X2 (SCMC); 
therefore, they are considered to have significant effects 
on the release of the drug from the controlled release 
matrix tablets after 4 hours. The quadratic response of CP 
(X12) and SCMC (X22), being significant, also has a more 
pronounced slowing effect on the release of the drug.
Polynomial Equation 7 shows the negative effect 
of both polymers at a 12-hour time interval. It is quite 
evident from Equation 7 that the slowing effect of the 
polymers is increased, and that CP has a comparatively 
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FIGURE 5 - Graphical representation of bioadhesive strengths 
required for the detachment of mucoadhesive tablets from a 
rabbit’s intestine.
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greater negative influence, showing more release-retarding 
ability of CP at 12 hours. Linear responses X1 (CP) and X2 
(SCMC), in the case of Y2, have P-values of 0.0003 and 
0.0009, respectively; therefore, they are also considered 
significant, but the quadratic response (X12) with a P-value 
of 0.1107 is not significant, which is represented in Table 
VII. The cross-product contribution (X1X2) for both of 
these response variables (Y1 and Y2) are not significant as 
P-values, for these are greater than 0.05.
Both linear terms, X1 (CP) and X2 (SCMC), are very 
influential as far as bioadhesive strength is concerned 
(as depicted in Equation 8 and Table VIII). Polynomial 
Equation 8 shows a more positive effect of CP, confirming 
the more mucoadhesive property of CP, as compared to 
SCMC. The P-value, being less than 0.05 for these linear 
terms, is considered significant. Polynomial Equation 
8 also shows the significance of the combined polymer 
effect on bioadhesion. The P-value for the cross-product 
contribution (X1X2) is 0.0272, which confirms the 
significance of the combined effect of both polymers on 
bioadhesion.
Response surface analysis
The response surface plot (Figure 6) and contour 
plot (Figure 7) show a steady-state decline in the value 
of release at 4 hours (rel4hrs), as the concentration of 
either polymer increases (i.e., CP and SCMC). However, 
the slowing influence of SCMC is somewhat more 
pronounced when compared to CP. The enhanced release-
slowing ability of SCMC was also observed by Singh et 
al. (2006) and Varshosaz et al. (2006). Similarly, a decline 
in the release of the drug reaches its maximum when the 
highest levels of both polymers are used (i.e., 125 mg for 
each polymer).
Figures 8 and 9 also depict linear trends in the 
release patterns of the drug, but in a descending order. 
The release rate of the drug decreases to a great extent 
with increasing amounts of polymers. At lower levels of 
both polymers, about 80% of the drug is released within 12 
hours, but as the level of the polymers increases, a gradual 
decline is observed in the release of the drug, and only 55% 
of the drug is released. By keeping SCMC concentrations 
TABLE VI - Analysis of variance for Y1
Source Sum of squares df Mean square F-value P-value Significance
Model 802.197 5 160.439 23.559 0.0003 S
X1 294.9 1 294.899 43.305 0.0003 S
X2 355.551 1 355.551 52.211 0.0002 S
X1.X2 9.47716 1 9.477 1.391 0.2767 NS
X12 81.0389 1 81.038 11.9 0.0107 S
X22 79.7854 1 79.785 11.716 0.0111 S
Residual 47.6691 7 6.809 ---- ---- ----
Lack of fit 46.9684 3 15.656 89.378 0.0004 S
Pure error 0.70067 4 0.175 ---- ---- ----
TABLE VII - Analysis of variance for Y2
Source Sum of squares df Mean square F-value P-value Significance
Model 2214.89 5 442.978 16.48 0.0009 S
X1 1150.18 1 1150.175 42.791 0.0003 S
X2 815.328 1 815.328 30.333 0.0009 S
X1.X2 6.692 1 6.692 0.248 0.6331 NS
X12 89.573 1 89.573 3.332 0.1107 NS
X22 182.331 1 182.331 6.783 0.0352 S
Residual 188.149 7 26.878 ---- ---- ----
Lack of fit 187.225 3 62.408 270.12 < 0.0001 S
Pure error 0.924 4 0.231 ---- ---- ----
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at a lower level and increasing the concentration of CP, a 
decline in the release of the drug can be confirmed.
The response surface plot and contour plot also 
explain the effect of polymers on the bioadhesive strength 
f of the matrix tablet. Figures 10 and 11 portray the linear 
fashion of the bioadhesive strength f in an ascending order 
with increasing amounts of polymers. However, the more 
pronounced effect of CP is observed when compared to 
SCMC, which is also observed in previous studies by 
Singh et al. (2006) and Suryakanta et al. (2011).
TABLE VIII - Analysis of variance for Y3
Source Sum of squares df Mean square F-value P-value Significance
Model 851.704 5 170.341 43.561 < 0.0001 S
X1 504.458 1 504.458 129 < 0.0001 S
X2 253.593 1 253.594 64.85 < 0.0001 S
X1.X2 30.25 1 30.25 7.736 0.0272 S
X12 61.053 1 61.053 15.613 0.0055 S
X22 6.445 1 6.445 1.648 0.2401 NS
Residual 27.373 7 3.91 ---- ---- ----
Lack of fit 22.573 3 7.524 6.27 0.0542 S
Pure error 4.8 4 1.2 ---- ---- ----
FIGURE 6 - Response surface plot showing the influence of 
CP and SCMC on the rel4hrs value of mucoadhesive tablet 
formulations of flurbiprofen.
FIGURE 7 - Contour diagram showing the influence of CP and 
SCMC on the rel4hrs value of mucoadhesive tablet formulations 
of flurbiprofen.
FIGURE 8 - Response surface plots showing the influence 
of CP and SCMC on the rel12hrs value of mucoadhesive tablet 
formulations of flurbiprofen.
FIGURE 9 - Contour diagram showing the influence of CP and 
SCMC on the rel12hrs value of mucoadhesive tablet formulations 
of flurbiprofen.
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FIGURE 10 - Response surface plot showing the influence 
of CP and SCMC on the value of bioadhesive strength (f) of 
mucoadhesive tablet formulations of flurbiprofen.
FIGURE 11 - Contour diagrams showing the influence of CP and 
SCMC on the value of bioadhesive strength of mucoadhesive 
tablet formulations of flurbiprofen.
CONCLUSION
Kinetic modeling showed that best fit model 
was the Korsmeyer–Peppas model, with non-Fickian 
diffusion tending towards zero-order release, indicating 
that the tablets can be successfully employed as a once 
daily, oral, controlled-release drug delivery system. The 
high bioadhesive strength of the tablets increases its 
gastrointestinal residence time and eventually improves 
the extent of bioavailability. However, proper balancing 
between the different levels of both polymers is necessary 
to attain proper bioadhesion, and the presence of CP is 
necessary for increased bioadhesion. FTIR studies of a 
selected formulation (F9) showed no combined effect 
by changing the peak symmetry and position. Therefore, 
it can be concluded that there is no interaction between 
the drug and formulation variables. A high degree of 
prediction obtained using RSM corroborates that a two-
factor CCD is quite efficient in optimizing drug delivery 
systems that exhibit non-linearity in response(s).
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